Abstract
Hereditary diffuse gastric cancer (HDGC) is a relatively rare disorder, with a mutated CDH1 gene as the only known cause. Carriers of a germline mutation in CDH1 have a lifetime risk of >80% of developing diffuse gastric cancer. As periodic gastric surveillance is of limited value in detecting early stages of HDGC, prophylactic gastrectomy is advised for this patient group. Little is known about other types of familial gastric cancer. The Dutch working group on hereditary gastric cancer has formulated guidelines for various aspects of medical management for families and individuals at high risk of developing gastric cancer, including criteria for referral, classification, diagnostics, and periodic gastric surveillance. These guidelines are not limited to HDGC and are therefore partially complementary to the guidelines on hereditary diffuse gastric cancer of the international gastric cancer linkage consortium (IGCLC 2010). In order to optimize the care and increase the knowledge on hereditary gastric cancer it is important to centralize medical care for these patients. National and international collaboration is warranted to improve the quality of research by increasing the size of study cohorts.
Similar content being viewed by others
References
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108. doi:10.3322/canjclin.55.2.74
Yamaoka Y, Kato M, Asaka M (2008) Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med 47:1077–1083. doi:10.2169/internalmedicine.47.0975
Helicobacter and Cancer Collaborative Group (2001) Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49:347–353. doi:10.1136/gut.49.3.347
Tsugane S, Sasazuki S (2007) Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 10:75–83. doi:10.1007/s10120-007-0420-0
Ladeiras-Lopes R, Pereira AK, Nogueira A et al (2008) Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer Causes Control 19:689–701. doi:10.1007/s10552-008-9132-y
Camargo MC, Anderson WF, King JB et al (2011) Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut [Epub ahead of print]
Lauren PA, Nevalainen TJ (1993) Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer 71:2926–2933. doi:10.1002/1097-0142(19930515)71:10<2926:AID-CNCR2820711007>3.0.CO;2-X
El-Rifai W, Powell SM (2002) Molecular and biologic basis of upper gastrointestinal malignancy. Gastric carcinoma. Surg Oncol Clin N Am 11:273–291. doi:10.1053/srao.2002.30815
Gonzalez CA, Sala N, Capella G (2002) Genetic susceptibility and gastric cancer risk. Int J Cancer 100:249–260. doi:10.1002/ijc.10466
Hemminki K, Li X, Czene K (2004) Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 108:109–114. doi:10.1002/ijc.11478
Lynch HT, Grady W, Suriano G, Huntsman D (2005) Gastric cancer: new genetic developments. J Surg Oncol 90:114–133. doi:10.1002/jso.20214
Fitzgerald RC, Hardwick R, Huntsman D et al (2010) Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet 47:436–444. doi:10.1136/jmg.2009.074237
Guilford P, Hopkins J, Harraway J et al (1998) E-cadherin germline mutations in familial gastric cancer. Nature 392:402–405. doi:10.1038/32918
Guilford P, Humar B, Blair V (2010) Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer 13:1–10. doi:10.1007/s10120-009-0531-x
Carneiro F, Huntsman DG, Smyrk TC et al (2004) Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 203:681–687. doi:10.1002/path.1564
Humar B, Guilford P (2009) Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Cancer Sci 100:1151–1157. doi:10.1111/j.1349-7006.2009.01163.x
Kluijt I, Siemerink E, Ausems MGEM et al (2011) CDH1 related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. Int J Cancer. doi:10.1002/ijc.26398 [Epub ahead of print]. PMID: 22020549
Norton JA, Ham CM, Van DJ et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245:873–879. doi:10.1097/01.sla.0000254370.29893.e4
Jakubowska A, Nej K, Huzarski T, Scott RJ, Lubinski J (2002) BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 87:888–891. doi:10.1038/sj.bjc.6600562
Friedenson B (2005) BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. Med Gen Med 7:60
Capelle LG, van Grieken NC, Lingsma HF et al (2010) Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 138:487–492. doi:10.1053/j.gastro.2009.10.051
Park SY, Ryu JK, Park JH et al (2011) Prevalence of gastric and duodenal polyps and risk factors for duodenal neoplasm in korean patients with familial adenomatous polyposis. Gut Liver 5:46–51. doi:10.5009/gnl.2011.5.1.46
Lynch HT, Snyder C, Davies JM et al (2010) FAP, gastric cancer, and genetic counseling featuring children and young adults: a family study and review. Fam Cancer 9:581–588. doi:10.1007/s10689-010-9353-7
Win AK, Hopper JL, Jenkins MA (2011) Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 10:1–9. doi:10.1002/ijc.25870
van Lier MG, Westerman AM, Wagner A et al (2011) High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut 60:141–147. doi:10.1136/gut.2010.223750
Pollock J, Welsh JS (2011) Clinical cancer genetics: part I: gastrointestinal. Am J Clin Oncol 34:332–336. doi:10.1097/COC.0b13e3181dea432
Masciari S, Dewanwala A, Stoffel EM et al (2011) Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 13:651–657. doi:10.1097/GIM.0b013e31821628b6
Stanich PP, Francis DL, Sweetser S (2011) The spectrum of findings in Cowden syndrome. Clin Gastroenterol Hepatol 9:e2–e3
Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJH (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439–449. doi:10.1016/S1470-2045(10)70070-X
Park CM, Reid PE, Walker DC, MacPherson BR (1987) A simple, practical ‘swiss roll’ method of preparing tissues for paraffin or methacrylate embedding. J Microsc 145:115–120
Correa P (2004) The biological model of gastric carcinogenesis. IARC Sci Publ 157:301–310
Author information
Authors and Affiliations
Corresponding author
Additional information
This study is conducted on behalf of the Dutch Working Group on Hereditary Gastric Cancer
Please refer the Appendix section for Dutch Working Group on Hereditary Gastric Cancer group members
Appendix
Appendix
Clinical Genetics: M. G. E. M. Ausems (Utrecht), N. Hoogerbrugge (Nijmegen), I. Kluijt (Amsterdam), R. H. Sijmons (Groningen), A. Wagner (Rotterdam)
Gastroenterologists: A. Cats, E. Dekker, K. Tytgat (Amsterdam), J. H. Kleibeuker (Groningen), H. F. A. Vasen (The Netherlands Foundation for Detection of Hereditary Tumours)
Molecular Genetics: M. Ligtenberg (Nijmegen)
Surgical Oncology: R. van Hillegersberg (Utrecht), J. T. Plukker (Groningen)
Pathology: N. C. T. van Grieken (Amsterdam), D. de Jong (Amsterdam), J. H. van Krieken (Nijmegen)
Psychology: E. Bleiker (Amsterdam)
Rights and permissions
About this article
Cite this article
Kluijt, I., Sijmons, R.H., Hoogerbrugge, N. et al. Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial Cancer 11, 363–369 (2012). https://doi.org/10.1007/s10689-012-9521-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-012-9521-y